SCHEMBL1664223

SCHEMBL1664223

COc1ccccc1-n1c(C(C)C)nc2cc(O)ccc2c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.55
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
L3MBTL1 Q9Y468 1/20 0.50
MAPT P10636 3/20 0.48
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 1/20 0.48
POLB P06746 1/20 0.48
RECQL P46063 1/20 0.48
APLNR P35414 3/20 0.47
TP53 P04637 2/20 0.47
LMNA P02545 2/20 0.47
MAPK1 P28482 2/20 0.46
NPC1 O15118 1/20 0.46
CASP3 P42574 1/20 0.46
HTT P42858 1/20 0.46
SENP8 Q96LD8 1/20 0.46
HSD17B10 Q99714 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1663953 0.83 TRPV1 (0.57) TRPV1MEN1KMT2AL3MBTL1MAPT
SCHEMBL1662144 0.83 TRPV1 (0.52) TRPV1MEN1KMT2AMAPTALDH1A1
SCHEMBL1664030 0.81 TRPV1 (0.57) TRPV1MEN1KMT2AMAPTALDH1A1
SCHEMBL23273575 0.81 TRPV1 (0.65) TRPV1KMT2AMAPTALDH1A1KDM4E
SCHEMBL29656833 0.81 TRPV1 (0.65) TRPV1KMT2AMAPTALDH1A1KDM4E
SCHEMBL1663160 0.80 TRPV1 (0.53) TRPV1MEN1KMT2AL3MBTL1MAPT
SCHEMBL1663899 0.79 TRPV1 (0.60) TRPV1MEN1KMT2AMAPTALDH1A1
SCHEMBL1663409 0.79 TRPV1 (0.69) TRPV1MEN1KMT2AL3MBTL1MAPT
SCHEMBL1665679 0.77 TRPV1 (0.55) TRPV1MEN1KMT2AMAPTTP53
SCHEMBL1553118 0.76 L3MBTL1 (0.61) MEN1KMT2AL3MBTL1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 TRPV1 1/4885MEN1 4252/4885KMT2A 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.